A Cluster of Long Non-coding RNAs Exhibit Diagnostic and Prognostic Values in Renal Cell Carcinoma

Overview

Journal Aging (Albany NY)

Specialty Geriatrics

Date 2019 Nov 16

PMID 31727869

Citations 25

Authors

Gong Cheng

Di Liu

Huageng Liang

Hongmei Yang

Ke Chen

Xiaoping Zhang

Affiliations

Soon will be listed here.

Abstract

Kidney cancer ranked in the top 10 for both men and women in the estimated numbers of new cancer cases in the United States in 2018. Targeted therapies have recently been administered to patients with clear cell renal cell carcinoma (ccRCC), but the overall survival of patients at the terminal stage of the disease has not been as good as expected. It is therefore necessary to uncover efficient biomarkers for early diagnosis, and to clarify the molecular mechanisms underlying ccRCC progression and metastasis. Increased evidence has shown that long non-coding RNAs (lncRNAs) play important roles during tumor progression. In this study, 10 candidate lncRNAs with diagnostic and prognostic values in ccRCC were identified: IGFL2-AS1, AC023043.1, AP000439.2, AC124854.1, AL355102.4, TMEM246-AS1, AL133467.3, ZNF582-AS1, LINC01510 and PSMG3-AS1. Enrichment analysis revealed metabolic and functional pathways, which may be closely associated with kidney cancer tumorigenesis. Six representative processes were summarized, namely glycolysis, amino acid metabolism, lipid synthesis, reductive carboxylation, nucleotide metabolism, transmembrane transport and signal transduction. In combination, the present results provided prognostic and diagnostic biomarkers for ccRCC and might pave the way for targeted intervention and molecular therapies in the future.

Citing Articles

Prognosis and progression of phagocytic regulatory factor-related gene combinations in clear cell renal cell carcinoma (ccRCC).

Xiao R, Luo Z, Huang H, Yin Y Transl Cancer Res. 2024; 13(9):4878-4895.

PMID: 39430817 PMC: 11483360. DOI: 10.21037/tcr-24-139.

Critical roles of lncRNA-mediated autophagy in urologic malignancies.

Gan L, Zheng L, Zou J, Luo P, Chen T, Zou J Front Pharmacol. 2024; 15:1405199.

PMID: 38939836 PMC: 11208713. DOI: 10.3389/fphar.2024.1405199.

High methylation of the same promoter of lncRNA / promotes malignant progression of esophageal cancer.

Li Z, Yan H, Wang B, Wang H, Chen A, Zhu T Epigenomics. 2024; 16(10):733-752.

PMID: 38869483 PMC: 11318746. DOI: 10.1080/17501911.2024.2342229.

Roles of lncRNAs in NF-κB-Mediated Macrophage Inflammation and Their Implications in the Pathogenesis of Human Diseases.

Shin J, Park J, Shin H, Arab I, Suk K, Lee W Int J Mol Sci. 2024; 25(5).

PMID: 38473915 PMC: 10931578. DOI: 10.3390/ijms25052670.

Disulfidptosis-associated LncRNAs index predicts prognosis and chemotherapy drugs sensitivity in cervical cancer.

Liu L, Liu J, Lyu Q, Huang J, Chen Y, Feng C Sci Rep. 2023; 13(1):12470.

PMID: 37528124 PMC: 10394072. DOI: 10.1038/s41598-023-39669-3.

References

Prensner J, Chinnaiyan A . The emergence of lncRNAs in cancer biology. Cancer Discov. 2011; 1(5):391-407. PMC: 3215093. DOI: 10.1158/2159-8290.CD-11-0209. View

Fischer K, Hoffmann P, Voelkl S, Meidenbauer N, Ammer J, Edinger M . Inhibitory effect of tumor cell-derived lactic acid on human T cells. Blood. 2007; 109(9):3812-9. DOI: 10.1182/blood-2006-07-035972. View

Qu L, Wang Z, Chen Q, Li Y, He H, Hsieh J . Prognostic Value of a Long Non-coding RNA Signature in Localized Clear Cell Renal Cell Carcinoma. Eur Urol. 2018; 74(6):756-763. DOI: 10.1016/j.eururo.2018.07.032. View

OLeary V, Hain S, Maugg D, Smida J, Azimzadeh O, Tapio S . Long non-coding RNA PARTICLE bridges histone and DNA methylation. Sci Rep. 2017; 7(1):1790. PMC: 5431818. DOI: 10.1038/s41598-017-01875-1. View

Sullentrop F, Hahn J, Moka D . In Vitro and In Vivo (1)H-MR Spectroscopic Examination of the Renal Cell Carcinoma. Int J Biomed Sci. 2013; 8(2):94-108. PMC: 3614866. View

Delage B, Fennell D, Nicholson L, McNeish I, Lemoine N, Crook T . Arginine deprivation and argininosuccinate synthetase expression in the treatment of cancer. Int J Cancer. 2010; 126(12):2762-72. DOI: 10.1002/ijc.25202. View

Xiong Z, Xiao W, Bao L, Xiong W, Xiao H, Qu Y . Tumor Cell "Slimming" Regulates Tumor Progression through PLCL1/UCP1-Mediated Lipid Browning. Adv Sci (Weinh). 2019; 6(10):1801862. PMC: 6523368. DOI: 10.1002/advs.201801862. View

Yang K, Lu X, Luo P, Zhang J . Identification of Six Potentially Long Noncoding RNAs as Biomarkers Involved Competitive Endogenous RNA in Clear Cell Renal Cell Carcinoma. Biomed Res Int. 2018; 2018:9303486. PMC: 6201332. DOI: 10.1155/2018/9303486. View

Cen C, Li J, Liu J, Yang M, Zhang T, Zuo Y . Long noncoding RNA LINC01510 promotes the growth of colorectal cancer cells by modulating MET expression. Cancer Cell Int. 2018; 18:45. PMC: 5861636. DOI: 10.1186/s12935-018-0503-5. View

10.

Tracy K, Tye C, Page N, Fritz A, Stein J, Lian J . Selective expression of long non-coding RNAs in a breast cancer cell progression model. J Cell Physiol. 2017; 233(2):1291-1299. PMC: 5673560. DOI: 10.1002/jcp.25997. View

11.

Mascaux C, Angelova M, Vasaturo A, Beane J, Hijazi K, Anthoine G . Immune evasion before tumour invasion in early lung squamous carcinogenesis. Nature. 2019; 571(7766):570-575. DOI: 10.1038/s41586-019-1330-0. View

12.

Gong J, Maia M, Dizman N, Govindarajan A, Pal S . Metastasis in renal cell carcinoma: Biology and implications for therapy. Asian J Urol. 2017; 3(4):286-292. PMC: 5730828. DOI: 10.1016/j.ajur.2016.08.006. View

13.

Lucarelli G, Loizzo D, Franzin R, Battaglia S, Ferro M, Cantiello F . Metabolomic insights into pathophysiological mechanisms and biomarker discovery in clear cell renal cell carcinoma. Expert Rev Mol Diagn. 2019; 19(5):397-407. DOI: 10.1080/14737159.2019.1607729. View

14.

Wettersten H, Abu Aboud O, Lara Jr P, Weiss R . Metabolic reprogramming in clear cell renal cell carcinoma. Nat Rev Nephrol. 2017; 13(7):410-419. DOI: 10.1038/nrneph.2017.59. View

15.

Zhou H, Tang K, Liu H, Zeng J, Li H, Yan L . Regulatory Network of Two Tumor-Suppressive Noncoding RNAs Interferes with the Growth and Metastasis of Renal Cell Carcinoma. Mol Ther Nucleic Acids. 2019; 16:554-565. PMC: 6506628. DOI: 10.1016/j.omtn.2019.04.005. View

16.

Rathmell W, Rathmell J, Linehan W . Metabolic Pathways in Kidney Cancer: Current Therapies and Future Directions. J Clin Oncol. 2018; :JCO2018792309. PMC: 6488445. DOI: 10.1200/JCO.2018.79.2309. View

17.

Hu X, Feng Y, Zhang D, Zhao S, Hu Z, Greshock J . A functional genomic approach identifies FAL1 as an oncogenic long noncoding RNA that associates with BMI1 and represses p21 expression in cancer. Cancer Cell. 2014; 26(3):344-357. PMC: 4159613. DOI: 10.1016/j.ccr.2014.07.009. View

18.

Cheville J, Lohse C, Zincke H, Weaver A, Blute M . Comparisons of outcome and prognostic features among histologic subtypes of renal cell carcinoma. Am J Surg Pathol. 2003; 27(5):612-24. DOI: 10.1097/00000478-200305000-00005. View

19.

Li J, Wei L . Increased expression of LINC01510 predicts poor prognosis and promotes malignant progression in human non-small cell lung cancer. Biomed Pharmacother. 2018; 109:519-529. DOI: 10.1016/j.biopha.2018.10.136. View

20.

Metallo C, Gameiro P, Bell E, Mattaini K, Yang J, Hiller K . Reductive glutamine metabolism by IDH1 mediates lipogenesis under hypoxia. Nature. 2011; 481(7381):380-4. PMC: 3710581. DOI: 10.1038/nature10602. View